منابع مشابه
Adjuvant therapy of pancreatic cancer.
Adjuvant therapy for pancreatic cancer remains controversial. However, both sides of the Atlantic Ocean agree that at least gemcitabine should be the pivotal agent offered to all patients. The role of radiation therapy remains somewhat inconclusive but chemoradiation, whether in the neoadjuvant or adjuvant setting is a standard option often utilized in the USA. This review is an update from the...
متن کاملAdjuvant therapy for pancreatic cancer.
Survival for patients with pancreas cancer is correlated to stage. Only 20% of patients present with localized disease amenable to potentially curative resection but, despite resection, the 5-year survival rate for early stage patients remains less than 25%. Current accepted standard of care is adjuvant gemcitabine following curative resection but there have been no conclusions regarding the ro...
متن کاملAdjuvant therapy in pancreatic cancer.
Pancreatic cancer is one of the major causes of cancer death in Europe with a 5-year survival rate of less than 5%. Although surgery cannot guarantee a cure, the 5-year survival does improve to around 10% following resection and increases to 20-30% with adjuvant chemotherapy. The European Study Group for Pancreatic Cancer (ESPAC) 1 trial was the first adequately powered, randomized study to ass...
متن کاملAdjuvant therapy for endometrial cancer
Endometrial cancer is a common gynecologic malignancy typically diagnosed at early stage and cured with surgery alone. Adjuvant therapy is tailored according to the risk of recurrence, estimated based on the International Federation of Gynecology and Obstetrics (FIGO) stage and other histological factors. The objective of this manuscript is to review the evidence guiding adjuvant therapy for ea...
متن کاملAdjuvant Systemic Therapy of Breast Cancer
patients younger than 50 years of 12%, and of endocrine therapy of 12%, as well as for patients older than 50 years with endocrine-responsive disease, with regard to disease-free survival with a follow-up time of 15 years [1]. In HER2/neu-overexpressing breast cancer there is an even larger benefit for patients treated with adjuvant chemotherapy in combination with the antibody trastuzumab (app...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Cancer
سال: 1978
ISSN: 0007-0920,1532-1827
DOI: 10.1038/bjc.1978.49